Silo Pharma, Inc. (SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as Alzheimer’s, PTSD, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which it believes will be transformative to the well-being of patients and the healthcare industry. The company already has 5 patents issued and provisional, 4 patents pending, and has 5 novel drug candidates that are under development for large, underserved medical markets.
Psychedelics are a class of psychoactive substances that contain chemical compounds which can produce changes in perception, mood and cognitive processing, and they can be found both in nature and manufactured in a laboratory.
In the past, psychedelics had somewhat of a bad name, with many associating their use with the countercultural explosion of the 1960s.
But scientists have known about their therapeutic potential for a long time, and recent studies have shown their potential in treating depression, anxiety, substance addiction, pain, PTSD and obsessive compulsive disorder.
Government regulator and public acceptance of psychedelics’ therapeutic potential is on the rise – the US Food & Drug Administration deemed psilocybin-assisted psychotherapy as a ‘Breakthrough Therapy’ in late 2019 and expanded access to MD-MA – a psychoactive drug more commonly known as ecstasy – to PTSD patients in clinical trials.
There’s plenty of science backing the use of psych-e-delics as therapeutics, and the global market opportunity has been estimated at a staggering $100 billion.(8)
One company that could be extremely well-positioned for this opportunity is Silo Pharma, Inc. (SILO)
With five novel drug candidates currently under development for large, underserved medical markets, including; Alzheimer’s Disease, Multiple Sclerosis, Rheumatoid Arthritis, Stress-induced psychiatric disorders, and
Fibromyalgia, Silo Pharma, Inc. (SILO) needs to be on your watch list right now!
Silo Pharma, Inc. (SILO) entered into a sponsored research agreement with Columbia University which Silo has been granted an option to license certain assets currently under development, including Alzheimer’s disease. (10)
This agreement incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology (in Psychiatry) at Columbia University Irving Medical Center. Denny and her team are focusing their efforts on the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer’s disease. (10)
An estimated 6.5 million Americans, including one in ten people, age 65 and older, currently live with Alzheimer’s disease.
Dr. Denny’s pioneering research into whether keta-mine and the novel inventions that may be licensed by Silo may improve memory retrieval, halt, or even reverse, the process of Alzheimer’s disease-related to memory loss or cognitive aging, could have life-altering implications for people suffering with everything from Alzheimer’s disease to post-traumatic stress disorder (PTSD).(10)
6.5 million Americans suffer from Alzheimer’s and related diseases
1 in 9 Americans 65+ have Alzheimer’s
U.S. market for relevant drugs expected to reach $5 billion by 2027
Developed by Columbia University
Novel drug combines two approved therapeutics
Targets NDMARS and 5HT4Rs to treat cognitive and neuropsychiatric symptoms in Alzheimer’s
26% of Americans 18+ suffer from anxiety, PTSD and other disorders
This number has escalated post-CV-19
U.S. market for relevant drugs expected to reach $13 billion by 2027
Metabolomic biomarkers predict response to pharmacological treatments
Utilizes keta-mine compositions as a method for treatment and prevention
Silo Pharma, Inc. (SILO) entered into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis. Silo Plans to explore the use of Psychedelics to Target Inflammation.
Silo Pharma, Inc and the University of Maryland, Baltimore to explore a novel invention generally known as “Joint-homing peptides for use in the investigation and treatment of arthritogenic processes.”
The ability of the peptides to target inflamed endothelium suggests they could be used to target drug delivery to the diseased joints. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug.
These peptides have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. The peptides could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.
“This option gives Silo access to a unique and potentially vital therapeutic that can also act as a drug delivery platform,” stated Eric Weisblum, Chairman and CEO of Silo Pharma(13).
“The ability to deliver compounds directly to targeted areas of the body with this technology could be revolutionary by increasing the efficacy of the treatment while reducing the amount of medication needed. There is a tremendous need for creative and unique therapeutics for patients suffering from rare diseases.(13)”
1.3M U.S. adults suffer from Rheumatoid Arthritis
The most common autoimmune disease in U.S.
U.S. market for Rheumatoid Arthritis drugs expected to reach $63 billion by 2027
Development plan to utilize liposomal homing peptide to deliver targeted psilocybin
Ability to target inflamed epithelium suggests possibility to target drug delivery
Approach could enhance therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug
Potential to develop fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis
Could be customizable and used to deliver nanoparticles for precise imaging
Could be used to treat autoimmune diseases other than Rheumatoid Arthritis
US Patent issued 11/16/21 #11174287 Central Nervous System Homing Peptides US #8,623,377 Joint-Homing peptide
U.S. Provisional Patent Application No. 63/060,573, titled “Central Nervous System Delivery of Psi-lo-cybin,” filed August 3, 2020
U.S. Provisional Patent Application No. 63/060,569, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psi-lo-cybin,” filed August 3, 2020
U.S. Provisional Patent Application No. 63/060,577, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psi-lo-cybin,” filed August 3, 2020
U.S. Provisional Patent Application No. 63/24,827, titled “Use of Psilocybin in Cancer Treatment,” filed December 13, 2020.
On September 27, 2022 Silo Pharma, Inc. (Nasdaq: SILO) (formerly OTCQB: SILO), announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share.
The gross proceeds to Silo Pharma from this offering are expected to be $5,000,000, before deducting the underwriting discount and other estimated offering expenses payable by Silo Pharma. Silo Pharma intends to use the net proceeds from the offering for product development, marketing, and working capital and general corporate purposes. A portion of the proceeds may also be used for acquisitions of complementary businesses, technologies, or other assets.
As a result of the offering, the Company’s common stock will become listed on the Nasdaq Capital Market and will trade under the ticker symbol “SILO” beginning September 27, 2022. The offering is expected to close on or about September 29, 2022, subject to customary closing conditions. In addition, the Company has granted a 45-day option to the underwriter to purchase up to an additional 150,000 shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments, if any.
Low float stocks are a subject of great interest for active market participants as they could potentially present significant swings to the upside single in a single day based on possible volatility. Due to the fact that low float stocks are very short numbered, they could present a tremendous opportunity in the event that demand surges. According to the company filing with the SEC on September 20, 2022 , Silo Pharma, Inc. (SILO) only has 2,576,142 shares outstanding.(3)
MEET THE BOARD
Chairman Of The Board
M.D., PH.D. Scientific Advi
MD / PHD Advisor
M.D., MBA Vice President of r&D
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage .We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Virtus Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications in incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Compensation: Pursuant to an agreement between TD Media LLC and Virtus Media LLC, Virtus Media LLC has been hired for a period beginning on 10/20/2022 and ending after one business day to publicly disseminate information about (SILO:US) via digital communications. We have been paid three thousand dollars USD via bank wire transfer.